TY - JOUR
T1 - The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer
AU - PIONEER Consortium
AU - EAU
AU - LU
AU - UNISR
AU - Erasmus
AU - UKE
AU - TAU
AU - KCL
AU - EORTC
AU - TTOP
AU - ICHOM
AU - ECPC
AU - ASSOC EISBM
AU - ICL
AU - Hyve
AU - EAPM
AU - PM
AU - WI
AU - UoA
AU - TUD
AU - Fraunhofer
AU - UGOT
AU - Radboud
AU - IHE
AU - Bayer AG
AU - SANOFI
AU - ASTELLAS
AU - SAS
AU - Janssen
AU - IQVIA
AU - eGF-eCancer
AU - AstraZeneca
AU - HelmHoltz
AU - Beyer, Katharina
AU - MacLennan, Sara J.
AU - Moris, Lisa
AU - Lardas, Michael
AU - Mastris, Ken
AU - Hooker, Gary
AU - Greene, Robert
AU - Briers, Erik
AU - Omar, Muhammad Imran
AU - Healey, Jemma
AU - Tripathee, Sheela
AU - Gandaglia, Giorgio
AU - Venderbos, Lionne D.F.
AU - Smith, Emma J.
AU - Bjorkqvist, Josefine
AU - Asiimwe, Alex
AU - Huber, Johannes
AU - Roobol, Monique J.
AU - Zong, Jihong
AU - Bjartell, Anders
AU - N'Dow, James
AU - Briganti, Alberto
AU - MacLennan, Steven
AU - Van Hemelrijck, Mieke
N1 - Publisher Copyright:
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Patients are the stewards of their own care and hence their voice is important when designing and implementing research. Patients should be involved not only as participants in research that impacts their care, as the recipients of that care and any associated harms, but also as research collaborators in prioritising important questions from the patient perspective and designing the research and the ways in which is it most appropriate to involve patients. The PIONEER Consortium, an international multistakeholder collaboration lead by the European Association of Urology, has developed a core outcome set (COS) for localised and metastatic prostate cancer relevant to all stakeholders in particular patients. Throughout the work of PIONEER, patient representatives were involved as collaborators in setting the research agenda, and a wider group of patients was involved as participants in developing COSs, for instance in consensus meetings on choosing important outcomes and appropriate definitions. This publication showcases the process for COS development and highlights the most important recommendations to ultimately inform future research projects co-created between patients and other stakeholders. PATIENT SUMMARY: An important step in involving patients in the selection of outcomes for clinical trials, clinical audits, and real-world evidence is the development of a core outcome set (COS) that is relevant to all stakeholders. This report highlights the patient participation throughout our PIONEER COS development. TAKE HOME MESSAGE: An important step in involving patients in the selection of outcomes for clinical trials, clinical audits, and real-world evidence is to develop a core outcome set (COS) that is relevant to all stakeholders. As part of the work of the PIONEER Consortium, we aim to highlight the patient participation throughout our PIONEER COS development.
AB - Patients are the stewards of their own care and hence their voice is important when designing and implementing research. Patients should be involved not only as participants in research that impacts their care, as the recipients of that care and any associated harms, but also as research collaborators in prioritising important questions from the patient perspective and designing the research and the ways in which is it most appropriate to involve patients. The PIONEER Consortium, an international multistakeholder collaboration lead by the European Association of Urology, has developed a core outcome set (COS) for localised and metastatic prostate cancer relevant to all stakeholders in particular patients. Throughout the work of PIONEER, patient representatives were involved as collaborators in setting the research agenda, and a wider group of patients was involved as participants in developing COSs, for instance in consensus meetings on choosing important outcomes and appropriate definitions. This publication showcases the process for COS development and highlights the most important recommendations to ultimately inform future research projects co-created between patients and other stakeholders. PATIENT SUMMARY: An important step in involving patients in the selection of outcomes for clinical trials, clinical audits, and real-world evidence is the development of a core outcome set (COS) that is relevant to all stakeholders. This report highlights the patient participation throughout our PIONEER COS development. TAKE HOME MESSAGE: An important step in involving patients in the selection of outcomes for clinical trials, clinical audits, and real-world evidence is to develop a core outcome set (COS) that is relevant to all stakeholders. As part of the work of the PIONEER Consortium, we aim to highlight the patient participation throughout our PIONEER COS development.
KW - Big data
KW - Core outcome set
KW - Patient involvement
KW - Patient participation
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85121946814&partnerID=8YFLogxK
U2 - 10.1016/j.euf.2021.09.008
DO - 10.1016/j.euf.2021.09.008
M3 - Article
C2 - 34602368
AN - SCOPUS:85121946814
SN - 2405-4569
VL - 7
SP - 943
EP - 946
JO - European Urology Focus
JF - European Urology Focus
IS - 5
ER -